This is on top of already discounted sales arrangements for Sunlenca® / Lenacapavir in about 120 emerging economy nations. And it is the responsible, moral and ethically-correct thing to do. The burden of AIDS remains staggering in much of the world — especially the areas least able to afford the next-gen therapeutics.
Here’s that from Reuters [but the more informed take belongs to my buddy Ed Silverman ($ subs. req.), over at Stat+ — do go read his, of yesterday].
…Gilead, a U.S. pharmaceutical company, granted six voluntary licences in 2024 to generic manufacturers across India, Egypt and Pakistan to produce and supply the drug to 120 low- and middle-income countries. These included South Africa, although there was criticism that no South African drugmakers were included.
A licence for a South African company would be the seventh such deal, potentially boosting access to a drug many HIV/AIDS experts have said could help bring an end to the 44-year-old pandemic by slashing the numbers of new infections.
Gilead said it has been open to adding an additional voluntary license for local manufacturing in Sub-Saharan Africa. “Gilead will review the proposals and assess whether required quality standards can be met before any voluntary license is granted,” the company said in an email….
Do well, by going good — indeed. Onward, smiling into a very London-, or Dublin-like morning again, here.
नमस्ते
Powerline Lies... 